Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

摘要: Based on the evidence that aripiprazole added to serotonin reuptake inhibitors (SRIs) or clomipramine in treatment-resistant obsessive-compulsive disorder (OCD) has reported promising results, present 16-week, double-blind, randomized, placebo-controlled trial had aim explore efficacy of add-on pharmacotherapy clinical symptoms and cognitive functioning a sample OCD patients receiving SRIs. After neurocognitive assessments, were randomly allocated receive, double-blind design, 15 mg/d placebo. A final 30 completed study. The results obtained indicate stable SRI treatment substantially improved as measured by changes Yale-Brown Obsessive Compulsive Scale total score subscores (obsessions, P = 0.007; compulsions, 0.001; score, < 0.0001). Regarding functions, improvement was observed some explored areas, such attentional resistance interference (Stroop 0.001) executive (perseverative errors, 0.015). findings provide augmentation SRIs/clomipramine is well tolerated may be proposed an effective therapeutic strategy improve outcome OCD.